Cervical intraepithelial neoplasia: Prognosis by combined LOH analysis of multiple loci

Gynecologic Oncology

Volumn 94, Issue 3, 2004, Pages 671-679

  Elhamidi, Amina ^a   Hamoudi, Rifat A ^a   Kocjan, Gabrijela ^a   Du, Ming Qing ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

CIN; HPV; LOH; Prognosis

Indexed keywords

HISTIDINE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BIOINFORMATICS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE DELETION; GENE IDENTIFICATION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RISK; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

ADULT; AGED; ALLELES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 6; FEMALE; GENE DELETION; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 4444258709     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.06.013     Document Type: Article

References (45)

1. Cirisano F.D. Management of pre-invasive disease of the cervix. Semin. Surg. Oncol. 16:1999;222-227
2. Bar-Am A., Daniel Y., Ron I.G., Niv J., Kupferminc M.J., Bornstein J., et al. Combined colposcopy, loop conization, and laser vaporization reduces recurrent abnormal cytology and residual disease in cervical dysplasia. Gynecol. Oncol. 78:2000;47-51
3. Milojkovic M. Residual and recurrent lesions after conization for cervical intraepithelial neoplasia grade 3. Int. J. Gynaecol. Obstet. 76:2002;49-53
4. Lorincz A.T., Reid R., Jenson A.B., Greenberg M.D., Lancaster W., Kurman R.J. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet. Gynecol. 79:1992;328-337
5. Jacobs M.V., Walboomers J.M., Snijders P.J., Voorhorst F.J., Verheijen R.H., Fransen-Daalmeijer N., et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int. J. Cancer. 87:2000;221-227
6. Kjaer S.K., van den Brule A.J., Paull G., Svare E.I., Sherman M.E., Thomsen M., et al. Specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ. 325:2002;572
7. Solomon D., Schiffman M., Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl. Cancer Inst. 93:2001;293-299
8. Nobbenhuis M.A., Walboomers J.M., Helmerhorst T.J., Rozendaal L., Remmink A.J., Risse E.K., et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 354:1999;20-25
9. Lazo P.A. The molecular genetics of cervical carcinoma. Br. J. Cancer. 80:1999;2008-2018
10. Giannoudis A., Herrington C.S. Human papillomavirus variants and squamous neoplasia of the cervix. J. Pathol. 193:2001;295-302
11. Kersemaekers A.M., Hermans J., Fleuren G.J., van de Vijver M.J. Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix. Br. J. Cancer. 77:1998;192-200
12. Kersemaekers A.M., Kenter G.G., Hermans J., Fleuren G.J., van de Vijver M.J. Allelic loss and prognosis in carcinoma of the uterine cervix. Int. J. Cancer. 79:1998;411-417
13. Senchenko V., Liu J., Braga E., Mazurenko N., Loginov W., Seryogin Y., et al. Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas. Oncogene. 22:2003;2984-2992
14. Skomedal H., Helland A., Kristensen G.B., Holm R., Borresen-Dale A.L. Allelic imbalance at chromosome region 11q23 in cervical carcinomas. Eur. J. Cancer. 35:1999;659-663
15. Kersemaekers A.M., van de Vijver M.J., Kenter G.G., Fleuren G.J. Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. Genes Chromosomes Cancer. 26:1999;346-354
16. Acevedo C.M., Henriquez M., Emmert-Buck M.R., Chuaqui R.F. Loss of heterozygosity on chromosome arms 3p and 6q in microdissected adenocarcinomas of the uterine cervix and adenocarcinoma in situ. Cancer. 94:2002;793-802
17. Chuaqui R., Silva M., Emmert-Buck M. Allelic deletion mapping on chromosome 6q and X chromosome inactivation clonality patterns in cervical intraepithelial neoplasia and invasive carcinoma. Gynecol. Oncol. 80:2001;364-371
18. Chung T.K., Cheung T.H., Lo W.K., Yu M.Y., Hampton G.M., Wong H.K. Loss of heterozygosity at the short arm of chromosome 3 in microdissected cervical intraepithelial neoplasia. Cancer Lett. 154:2000;189-194
19. Guo Z., Hu X., Afink G., Ponten F., Wilander E., Ponten J. Comparison of chromosome 3p deletions between cervical precancers synchronous with and without invasive cancer. Int. J. Cancer. 86:2000;518-523
20. Harima Y., Sawada S., Nagata K., Sougawa M., Ohnishi T. Chromosome 6p21.2, 18q21.2 and human papilloma virus (HPV) DNA can predict prognosis of cervical cancer after radiotherapy. Int. J. Cancer. 96:2001;286-296
21. Chatterjee A., Pulido H.A., Koul S., Beleno N., Perilla A., Posso H., et al. Mapping the sites of putative tumor suppressor genes at 6p25 and 6p21.3 in cervical carcinoma: occurrence of allelic deletions in precancerous lesions. Cancer Res. 61:2001;2119-2123
22. Pulido H.A., Fakruddin M.J., Chatterjee A., Esplin E.D., Beleno N., Martinez G., et al. Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. Cancer Res. 60:2000;6677-6682
23. Saxon P.J., Srivatsan E.S., Stanbridge E.J. Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. EMBO J. 5:1986;3461-3466
24. Steenbergen R.D., Walboomers J.M., Meijer C.J., van der Raaij-Helmer E.M., Parker J.N., Chow L.T., et al. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Oncogene. 13:1996;1249-1257
25. Hamidi A.E., Liu H., Zhang Y., Hamoudi R., Kocjan G., Du M.Q. Archival cervical smears: a versatile resource for molecular investigations. Cytopathology. 13:2002;291-299
26. Lakhani S.R., Slack D.N., Hamoudi R.A., Collins N., Stratton M.R., Sloane J.P. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab. Invest. 74:1996;129-135
27. Ostwald C., Muller P., Barten M., Rutsatz K., Sonnenburg M., Milde-Langosch K., et al. Human papillomavirus DNA in oral squamous cell carcinomas and normal mucosa. J. Oral Pathol. Med. 23:1994;220-225
28. Karlsen F., Kalantari M., Jenkins A., Pettersen E., Kristensen G., Holm R., et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J. Clin. Microbiol. 34:1996;2095-2100
29. Miller C.S., Zeuss M.S., White D.K. Detection of HPV DNA in oral carcinoma using polymerase chain reaction together with in situ hybridization. Oral Surg. Oral Med. Oral Pathol. 77:1994;480-486
30. Yoshino K., Enomoto T., Nakamura T., Sun H., Ozaki K., Nakashima R., et al. Alterations in cancerous and non-cancerous cervical epithelium. Int. J. Cancer. 85:2000;6-13
31. Butler D., Collins C., Mabruk M., Barry W.C., Leader M.B., Kay E.W. Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features. J. Pathol. 192:2000;502-510
32. Helland A., Kraggerud S.M., Kristensen G.B., Holm R., Abeler V.M., Huebner K., et al. Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival. Int. J. Cancer. 88:2000;217-222
33. Wilke C.M., Hall B.K., Hoge A., Paradee W., Smith D.I., Glover T.W. FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum. Mol. Genet. 5:1996;187-195
34. Thorland E.C., Myers S.L., Gostout B.S., Smith D.I. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene. 22:2003;1225-1237
35. Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J., et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 84:1996;587-597
36. Birrer M.J., Hendricks D., Farley J., Sundborg M.J., Bonome T., Walts M.J., et al. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res. 59:1999;5270-5274
37. Baykal C., Ayhan A., Al A., Yuce K., Ayhan A. No relationship is indicated between FHIT expression and clinicopathologic prognostic parameters in early stage cervical carcinoma. Int. J. Gynecol. Cancer. 13:2003;192-196
38. Butler D., Collins C., Mabruk M., Leader M.B., Kay E.W. Loss of FHIT expression as a potential marker of malignant progression in preinvasive squamous cervical cancer. Gynecol. Oncol. 86:2002;144-149
39. Connolly D.C., Greenspan D.L., Wu R., Ren X., Dunn R.L., Shah K.V., et al. Loss of FHIT expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin. Cancer Res. 6:2000;3505-3510
40. Conneely O.M., Mulac-Jericevic B., DeMayo F., Lydon J.P., O'Malley B.W. Reproductive functions of progesterone receptors. Recent Prog. Horm. Res. 57:2002;339-355
41. Hanekamp E.E., Kuhne E.C., Smid-Koopman E., de Ruiter P.E., Chadha-Ajwani S., Brinkmann A.O., et al. Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer. Eur. J. Cancer. 38(Suppl 6):2002;S71-S72
42. Dai D., Wolf D.M., Litman E.S., White M.J., Leslie K.K. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res. 62:2002;881-886
43. Gabra H., Langdon S.P., Watson J.E., Hawkins R.A., Cohen B.B., Taylor L., et al. Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer. Clin. Cancer Res. 1:1995;945-953
44. Shen K., Yueng W., Ngan H. Estrogen and progesterone receptors in normal cervix and primary cervical carcinoma. Chin. Med. J. (Engl.). 107:1994;648-652
45. Sadan O., Frohlich E.P., Driscoll J.A., Apostoleris A., Savage N., Zakut H., et al. Is it safe to prescribe hormonal contraception and replacement therapy to patients with premalignant and malignant uterine cervices? Gynecol. Oncol. 34:1989;159-163